Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GNC's New Partner Brings China Access And Funding, Takes Board Seats

This article is powered by The Rose Sheet

Executive Summary

As GNC reports substantially trimming its net losses in its 2017 fourth-quarter and full-year results, it announces Harbin Pharmaceutical will invest around $300m in GNC, becoming the single largest shareholder, and the two firms will form a JV for manufacturing, marketing and distributing GNC-branded products in China. With the investment, GNC's board expands from six to 11 members, comprising GNC CEO Ken Martindale, five appointed by Harbin and five by GNC.

Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS121470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel